Five-Year Therapy with Recombinant Human Insulin-Like Growth Factor-1 in a Patient with PAPP-A2 Deficiency

Conclusion: Therapy with rhIGF-1 modestly improved linear growth in one patient with PAPPA-2 deficiency, but without true catch-up. Therapy was associated with pseudotumor cerebri in a sibling . Initial improvement in BMD and glycemic pattern on rhIGF-1 was not sustained during puberty.
Source: Hormone Research in Paediatrics - Category: Endocrinology Source Type: research